AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.82−0.10 (-1.69%)
Close on Nov 18, 2026Market cap $145.50KP/E –Yield –
AgomAb Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was -€62.55M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€62.55M | – |
| FY2024 | Dec 31, 2024 | -€46.27M | – |
| FY2023 | Dec 31, 2023 | -€11.39M | – |
See a number that looks wrong?